Who are carboplatin paclitaxel bevacizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with bevacizumab, Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carboplatin-paclitaxel-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

carboplatin paclitaxel bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

carboplatin paclitaxel bevacizumab (carboplatin paclitaxel bevacizumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with anti-angiogenic monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy combination with anti-angiogenic monoclonal antibody DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

carboplatin paclitaxel bevacizumab (carboplatin paclitaxel bevacizumab) — Gruppo Oncologico Italia Meridionale. This combination uses carboplatin and paclitaxel as chemotherapy agents to damage cancer cell DNA and disrupt microtubules, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
carboplatin paclitaxel bevacizumab TARGET	carboplatin paclitaxel bevacizumab	Gruppo Oncologico Italia Meridionale	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab)
FOLFOXIRI with bevacizumab	FOLFOXIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)
FOLFOX/ FOLFIRI with bevacizumab	FOLFOX/ FOLFIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (chemotherapy); VEGF (bevacizumab)
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with anti-angiogenic monoclonal antibody class)

Dutch Colorectal Cancer Group · 2 drugs in this class
Gruppo Oncologico Italia Meridionale · 1 drug in this class
Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). carboplatin paclitaxel bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/carboplatin-paclitaxel-bevacizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab